Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation
|ClinicalTrials.gov Identifier: NCT01315951|
Recruitment Status : Unknown
Verified March 2011 by Genesys Regional Medical Center.
Recruitment status was: Recruiting
First Posted : March 16, 2011
Last Update Posted : March 16, 2011
|Condition or disease||Intervention/treatment||Phase|
|Seborrheic Dermatitis||Biological: Petroleum Jelly||Not Applicable|
Nonscalp seborrheic dermatitis (NSSD) is typically a benign inflammatory process of the skin that affects oil rich areas including in and between eyebrows, paranasal area, behind ears, over the sternum, and groin. While these lesions typically come and go without proposing a threat to the patient, they can be socially debilitating, and psychologically distressing.
The mainstay treatment for an exacerbation of NSSD is topical steroids. Topical steroids are very effective and useful to patient's who are desperately seeking treatment. However, most family practitioners are reluctant to prescribe or recommend topical steroids for chronic conditions like NSSD due to the potential side-effects including permanent atrophy of the skin.
NSSD has an unknown etiology. However, one of its biggest risk factors appears to be dry skin due to its increase in incidence during colder seasons, and with use of alcohol-containing topicals. Naturally occurring skin yeast (ie Malassezia) are also thought to play a part.
Petrolatum is considered a skin protectant and has a strong ability to hold moisture in skin. Along with restricting water from leaving skin, it also decreases most air from contacting the skin. This may slow the growth and activity of skin yeast that are typically considered facultative anaerobes.
A patient diagnosed with nonscalp seborrheic dermatitis will be consented into the study and given instructions on the petroleum treatment. This includes wetting the affected area, blotting dry, and then applying petrolatum to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient will come back to the office for follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome. Pictures will be taken at each encounter and used to measure progress through one mm graphs. Patients will not be identifiable in these pictures, and they will be labeled with the patient's given ID number.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||8 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation|
|Study Start Date :||March 2011|
|Estimated Primary Completion Date :||February 2012|
|Estimated Study Completion Date :||March 2012|
Experimental: Petroleum Jelly
Every patient will be applying petroleum jelly to the affected areas per protocol.
Biological: Petroleum Jelly
Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
Other Name: Petrolatum, Vaseline
- Measuring the Effectiveness of Petroleum Jelly in Treating Nonscalp Seborrheic Dermatitis [ Time Frame: 4 weeks ]Petroleum jelly will be applied to the areas of the face affected by Nonscalp Seborrheic Dermatitis every other night for four weeks. Patients will be seen in the office at one week, two weeks, and one month during the course of the treatment. Pictures will be taken at each visit to determine the progress of the treatment.
- Patient Satisfaction ofTreatment [ Time Frame: 4 weeks ]Patients will be surveyed initially when they are consented asking about their personal history of nonscalp seborrheic dermatitis including triggers and previous and current treatment measures.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01315951
|Contact: Ryan D Stevenson, BSemail@example.com|
|Contact: Lauren E Suchy, BS, MPAfirstname.lastname@example.org|
|United States, Michigan|
|Genesys East Flint Campus||Recruiting|
|Burton, Michigan, United States, 48509|
|Contact: Ryan D Stevenson, BS 810-252-4951 email@example.com|
|Contact: Lauren E Suchy, BS, MPA 810-606-7878 firstname.lastname@example.org|
|Principal Investigator: Ryan D Stevenson, DS|
|Principal Investigator:||Ryan D Stevenson, BS||Genesys Regional Medical Center|